 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BURLINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...

Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates

Minerva Neurosciences, Inc. (NASDAQ:NERV  Get Free Report) was the target of a large decrease in short interest in the month of August. As of August 15th, there was short interest totalling...

Minerva Neurosciences, Inc. (NASDAQ:NERV) Short Interest Down 17.0% in August

Minerva Neurosciences: There's Probably Time For One More Rally

StockNews.com lowered shares of Minerva Neurosciences (NASDAQ:NERV  Free Report) from a hold rating to a sell rating in a research note issued to investors on Wednesday morning. Separately, HC...

Minerva Neurosciences (NASDAQ:NERV) Downgraded by StockNews.com

Minerva Neurosciences (NASDAQ:NERV Get Free Report) was downgraded by equities researchers at StockNews.com from a hold rating to a sell rating in a report released on Wednesday. Separately, HC Wainwright lifted their target price on Minerva Neurosciences from $8.00 to $11.00 and gave the company a ...

Minerva Neurosciences (NASDAQ:NERV) Rating Lowered to Sell at StockNews.com

Minerva Neurosciences, Inc. (NASDAQ:NERV  Free Report)  HC Wainwright dropped their Q3 2023 earnings per share estimates for shares of Minerva Neurosciences in a research report issued to clients and investors on Wednesday, August 2nd. HC Wainwright analyst D. Tsao now forecasts that ...

Q3 2023 EPS Estimates for Minerva Neurosciences, Inc. Lowered by Analyst (NASDAQ:NERV)

Minerva Neurosciences, Inc. (NASDAQ:NERV  Free Report)  Equities researchers at HC Wainwright issued their Q1 2024 earnings per share estimates for shares of Minerva Neurosciences in a note issued to investors on Wednesday, August 2nd. HC Wainwright analyst D. Tsao expects that the ...

Minerva Neurosciences, Inc. (NASDAQ:NERV) Expected to Post Q1 2024 Earnings of ($1.00) Per Share

StockNews.com upgraded shares of Minerva Neurosciences (NASDAQ:NERV Free Report) from a sell rating to a hold rating in a report issued on Tuesday. Minerva Neurosciences Trading Down 4.1 % NERV opened at $9.70 on Tuesday. Minerva Neurosciences has a 12-month low of $1.26 and a 12-month high of $15....

StockNews.com Upgrades Minerva Neurosciences (NASDAQ:NERV) to "Hold"

Minerva Neurosciences (NASDAQ:NERV  Get Free Report) was downgraded by equities research analysts at StockNews.com from a hold rating to a sell rating in a report released on Friday. Minerva Neurosciences Trading Up 2.3 % NASDAQ NERV opened at $12.07 on Friday. The...

Minerva Neurosciences (NASDAQ:NERV Free Report) was upgraded by analysts at StockNews.com from a sell rating to a hold rating in a note issued to investors on Thursday. Separately, HC Wainwright reaffirmed a neutral rating and issued a $8.00 target price on shares of Minerva Neurosciences in a ...

Minerva Neurosciences (NASDAQ:NERV) Stock Rating Upgraded by StockNews.com

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

Watchers	9,717
52-Wk Low	$1.26
52-Wk High	$13.22

Market Cap	$50.7M
Volume (M)	79,037.00
52-Wk High	$13.22
52-Wk Low	$1.26

NERV Minerva Neurosciences Inc

About

Feed

News

Sentiment

Earnings

Fundamentals